Related Experiment Video
Updated: Dec 7, 2025

Veno-Venous Extracorporeal Membrane Oxygenation in a Mouse
Published on: October 24, 2018
EP-7041, a Factor XIa Inhibitor as a Potential Antithrombotic Strategy in Extracorporeal Membrane Oxygenation: A
Charles V Pollack1,2, Michael A Kurz2, Neil J Hayward2
1Department of Emergency Medicine, University of Mississippi Medical Center, Jackson, MS.
Objectives:
Current approaches to systemic antithrombotic therapy in support of extracorporeal membrane oxygenation are limited and are hampered by both thrombotic and hemorrhagic complications. An alternative approach is needed.
Design:
Inhibition of coagulation factor XI/activated factor XI is an appealing pathway for antithrombotic support of extracorporeal membrane oxygenation. Selective inhibition of the contact pathway of coagulation could reduce bleeding risk, and because factor XI is linked with the inflammatory and complement systems, it can also be viewed as a biologically plausible target for the prevention of abnormal thrombosis during extracorporeal membrane oxygenation.
Conclusions:
We introduce initial information on EP-7041, a parenteral, potent, and selective, small-molecule activated factor XIa inhibitor with pharmacodynamic and pharmacokinetic characteristics that appear well suited for use in a critical care environment.
Related Concept Videos
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Venous Thrombosis III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pulmonary Embolism III: Nursing Management

